Drug and Device World

[druganddeviceworld]

Urologic Health secures $11 million for non-invasive bladder monitoring Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.... https://druganddeviceworld.com/2026/06/02/urologic-health-secures-11-million-for-non-invasive-bladder-monitoring/

Urologic Health secures $11 million for non-invasive bladder monitoring

[druganddeviceworld]

#HemophiliaA news: Phase 3 data in NEJM show Novo Nordisk's denecimig (Mim8) slashed bleeding rates vs standard care, with or without inhibitors. Up to 95% bleed‑free. #Mim8 #NEJM #HemophiliaTreatment

Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors 

[druganddeviceworld]

From a gut 'reset' to keep weight off after GLP-1s, to the double hit of stress & late-night eating on your microbiome, plus rising rectal cancer deaths in millennials—DDW 2026 highlights are here. #DDW2026 #GutHealth #Microbiome #ColorectalCancer #WeightLoss

From Gut Resets to Microbiome Rejuvenation: DDW 2026 Highlights Transformative Approaches to Digestive Health

[druganddeviceworld]

Continuous monitoring is filling the gaps in clinical trials. Jiang Li (Vivalink CEO) explains how physiologic data boosts safety, efficacy & cuts sample size. #ClinicalTrials #WearableTech #DigitalBiomarkers #ContinuousMonitoring

Beyond the Snapshot: Continuous physiologic monitoring in clinical trials

[druganddeviceworld]

New survey by Phenomix Sciences: 57% of obesity patients unaware of non-GLP-1 options like Qsymia, but after education, 68% shifted views—25% more open to alternatives. #ObesityCare #GLP1 #PatientEducation #PersonalizedMedicine #News

Patients open to non-GLP-1 drugs after education, survey finds

[druganddeviceworld]

New data from VESALIUS-CV: Repatha reduced risk of first major CV event by 31% in high-risk diabetes patients without known significant atherosclerosis. Median LDL-C achieved: 44 mg/dL. #News #ACC26 #CardioTwitter #PCSK9 #LDL #PrimaryPrevention

ACC26: Amgen’s Repatha cuts first major CV event risk by 31%

[druganddeviceworld]

Pharma traded clinical claims for cultural currency at this year’s Super Bowl—but the FDA’s warning to Novo Nordisk shows emotional resonance has limits. Behavioral science is the new frontier in health marketing. #PharmaMarketing #SuperBowl #HealthTech #BehavioralScience #FDA

From data to desire: How Pharma learned to win the Super Bowl

[druganddeviceworld]

The psychedelic renaissance is here. 🧠 Our latest feature explores how LSD is being rigorously researched for anxiety & depression. We spoke with Definium's Dr. Dan Karlin about the science, the stigma, and the future of mental health care. #MentalHealth #LSD #PsychedelicScience #DrugDevelopment

How LSD and classic psychedelics are re-entering modern psychiatry

[druganddeviceworld]

90% of drugs fail in humans after succeeding in mice. 🧪 Why? Animal models can't capture human complexity. Revalia Bio's Dr. Jenna DiRito explains how ex vivo human organs are bridging the translation gap. 🧠 #PreclinicalResearch #Biotech #HumanTissue #RevaliaBio

How human organs are rewriting the rules of drug development

[druganddeviceworld]

Duke's Dr. Amanda Randles explains how #DigitalTwins move medicine beyond static snapshots to dynamic, personalized care. Combining #AI, wearables & supercomputing to predict disease before symptoms appear. #HealthTech #AI #FutureOfMedicine #DigitalHealth

How digital twins are pioneering a new era of personalized, longitudinal healthcare

[druganddeviceworld]

"I didn't leave medicine—I'm just practicing it differently." 🩺 Former GP Dr Bryony Henderson on evolving from frontline care to system-wide impact as Head Medical Director at HeliosX. #HealthcareCareers #ClinicalLeadership #PhysicianBurnout #HealthTech #CareerPivot #MedicalDirector #HeliosX

Scaling impact without leaving medicine 

[druganddeviceworld]

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients. #News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

ECCO26 data reinforce long-term durability and real-world impact of AbbVie's IBD portfolio

[druganddeviceworld]

J.D. Mowery of Bora Pharmaceuticals explains why "friendshoring" is more than a buzzword—it's about patient-centric supply chains, geopolitical resilience, and rethinking manufacturing strategy for 2026 and beyond. #News #Pharma #SupplyChain #Friendshoring #CDMO #Manufacturing #BoraPharmaceuticals

Why Pharma can't ignore friendshoring in supply chain

[druganddeviceworld]

Sensei Biotherapeutics stock skyrockets 206% after acquiring Faeth Therapeutics and securing $200M private placement. The deal advances PIKTOR, a promising PI3K/mTOR inhibitor for endometrial and breast cancer. #News #SenseiBio #Biotech #CancerResearch #StockNews #PIKTOR

Sensei Bio stock skyrockets on acquisition and $200m financing

[druganddeviceworld]

Evogene and QUT team up to fight chemotherapy resistance in lung cancer using AI. The collaboration targets cellular pathways to develop new therapies for patients with limited options. #News #Evogene #QUT #AI #CancerResearch #LungCancer #Biotech #DrugDiscovery

Evogene and Australian Uni partner to tackle chemotherapy resistance in lung cancer

[druganddeviceworld]

Seamflow raises $4.5M to bring AI to the Testing, Inspection and Certification industry. Its platform tackles certification backlogs—cutting medical device approval times from 20+ months. #News #MedTech #AI #HealthTech #VentureCapital #TIC

Seamflow secures $4.5m to deploy AI for testing and certification bottlenecks

[druganddeviceworld]

FDA clears RevealDx's AI-powered lung nodule software to help radiologists assess cancer risk. The tool integrates directly into PACS and is now Medicare reimbursable. #News #HealthTech #AI #FDA #LungCancer #MedicalImaging #Radiology

RevealDx wins FDA clearance for lung nodule assessment software